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Abstract 
Background: we have recently shown that Tel-eVax, a genetic vaccine targeting dog telomerase (dTERT) and based 
on Adenovirus (Ad)/DNA Electro-Gene-Transfer (DNA–EGT) technology can induce strong immune response and 
increase overall survival (OS) of dogs affected by multicentric Diffuse Large B cell Lymphoma (DLBCL) when combined 
to COP therapy in a double-arm study. Here, we have utilized a clinically validated device for veterinary electropora-
tion called Vet-ePorator™, based on Cliniporator™ technology currently utilized and approved in Europe for electro-
chemotherapy applications and adapted to electrogenetransfer (EGT).
Methods: 17 dogs affected by DLBCL were vaccinated using two Ad vector injections (Prime phase) followed by 
DNA–EGT (Boost phase) by means of a Vet-ePorator™ device and treated in the same time with a 27-week Madison 
Wisconsin CHOP protocol. The immune response was measured by ELISA assays using pool of peptides.
Results: No significant adverse effects were observed. The OS of vaccine/CHOP animals was 64.5 weeks, in line with 
the previous study. Dogs developed antibodies against the immunizing antigen.
Conclusions: Tel-eVax in combination with CHOP is safe and immunogenic in lymphoma canine patients. These 
data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other 
cancer types. More importantly, our findings may translate to human clinical trials and represent new strategies for 
cancer treatment.
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Background
Lymphoma is one of the most common malignancies 
diagnosed in pet dogs in the United States [1, 2]. Among 
these canine lymphoma accounts for up to 24% of all 
reported neoplasms and the majority (60–80%) arises 
from malignant B cells. The most common presentation 
is a generalized multicentric lymphadenopathy corre-
sponding from stage III to V of the disease, with stage V 
describing tumor in blood, bone marrow, and other organ 
systems [3]. The current standard-of-care for canine Dif-
fuse Large B-cell Lymphoma (DLBCL) is the combination 
chemotherapy regimen of cyclophosphamide, vincris-
tine and prednisolone (COP) or cyclophosphamide, 
vincristine, doxorubicin, and prednisone (CHOP) regi-
men with or without l-asparaginase [4–7]. Negative 
prognostic factors, including, but not limited to, sub-
stage b, T-cell immunophenotype, chronic inflamma-
tion, advanced stage and high body weight can reduce 
this expected survival time significantly [1, 2, 8–13]. A 
recent study analysed the survival data in 598 dogs and 
showed geographic differences in the first remission 
durations of pet dogs diagnosed and treated at referral 
institutions with CHOP chemotherapy in the continental 
United States [14]. The median PFS for all B cell-LSA was 
234  days (interquartile range 109–343  days) and was in 
line with other studies [4, 15, 16]. In the northern United 
States (Connecticut, Illinois, Indiana, Iowa, Massachu-
setts, Michigan, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island and Wisconsin), the median 
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In humans, DLBCL is the most common high-grade 
non-Hodgkin lymphoma. Immunochemotherapy with 
rituximab and CHOP (R-CHOP) is the current first-line 
treatment [17]. However, with this therapeutic approach 
up to 40% of patients experience early treatment failure or 
relapse after initial response [18]. Table 1 reports a side-by-
side comparison and the current therapeutic approaches 
for human [19, 20] and canine DLBCL [21]. Considering 
the average life span of dogs and humans (about sevenfold 
difference), this further confirms the high translational 
relevance of canine patients in Comparative Oncology 
initiatives.
Telomerase is a ribonucleoprotein comprising an RNA 
component and a catalytic protein component (telomer-
ase reverse transcriptase, TERT) [22, 23]. As reported for 
other species, telomerase activity has been observed in 
the majority (> 90%) of canine tumors [24] contributing to 
maintenance of telomere length in cancer cells. Telomerase 
expression and telomere maintenance are critical for cell 
proliferation and survival in hematological malignancies 
[25].
Genetic vaccines are emerging among the most promis-
ing methodologies in cancer treatment. Evidence points 
towards the genetic immunization modality (heterologous 
prime/boost) as a powerful approach to induce superior 
immune responses and achieve greater clinical efficacy 
[26–30], including veterinary [31] and translational oncol-
ogy [32].
We have recently shown that Tel-eVax, a genetic vaccine 
based on Adenovirus (Ad) and DNA Electro-Gene-Trans-
fer (DNA–EGT) and targeting dTERT was able to induce 
strong immune response in dogs affected by B-cell LSA. 
Most importantly, COP regimen did not interfere with the 
effects of the immunotherapy and the survival of canine 
lymphoma was significantly augmented in comparison to 
chemotherapy treated subjects in two different studies [33, 
34].
In this study, we evaluated the impact of Tel-eVax in 
association with CHOP chemotherapy. In addition, we 
have tested the presence of anti-TERT antibodies as poten-
tial surrogate efficacy biomarkers.
Methods
Study design
From September 2010 to July 2017, 45 client-owned dogs 
with multicentric DLBCL were evaluated and 17 enrolled 
in the study. For each dog, the veterinary staff of the Vet-
erinary Oncology Services (VOS) performed a full initial 
clinical examination and administered both the chemo-
therapy and the immunotherapy. Every patient had a his-
topathologic or cytologic diagnosis of DLBCL (using the 
immunophenotype assessment) and an informed consent 
was distributed and approved by the owners.
Blood tests
Complete blood count, serum biochemical profile of at 
least 10–12 analytes (including total protein, albumin, 
urea, creatinine, alanine aminotransferase, aspartate 
aminotransferase, alkaline phosphatase, gamma-gluta-
myltransferase, calcium, phosphorus, iron, cholesterol, 
glucose, sodium, potassium in serum) and urinalysis were 
obtained from each patient. When elected by the owner, 
full staging was also performed.
Dogs immunization
The genetic components of Tel-eVax (Ad6-dTERTopt 
and pV1J-dTERT.LTBopt) have been described elsewhere 
[35]. Briefly, Ad6-dTERTopt expresses a codon optimized, 
catalytically inactive (D702A, V703I) full length canine 
telomerase and pV1J-dTERT.LTBopt encodes the same 
cDNA fused at N-term with tissue plasminogen activator 
(TPA) leader sequence and at the C-term with the codon 
optimized B subunit of E. coli heat-labile enterotoxin 
(LTB). For Ad vaccination (prime), dogs were injected 
in the biceps femoris muscle with a dose of  1011 Ad viral 
particles (vp). The DNA injection (boost) consisted of a 
1 ml solution (split over two injection sites with 0.5 ml/
site) containing 5  mg pV1J-dTERT.LTBopt in the dogs’ 
tibialis cranialis muscle. Dogs received two Ad6-dTER-
Topt injections followed by one or more cycles, each 
composed of 3× DNA–EGT. The electroporation was 
carried out with Vet-ePorator™, a device manufactured 
by IGEA (Carpi, Modena, Italy) for Evvivax and based 
on  Cliniporator® Technology. Electrical conditions con-
sisted of 8 square unipolar pulses at 110  V, at an inter-
val of 120  ms. The pulse length was 20  ms/phase with 
a frequency of 8  Hz. The total treatment lasts less than 
10 s. Dogs were anesthetized to carry out the electropo-
ration with propofol induction and either Isofluorane or 
Sevofluorane inhalant anesthesia with oxygen. The entire 
electroporation procedure, including anesthesia, lasted 
Table 1 comparison between human and canine DLBCL
Species Median age of occurrence Molecular biomarkers Current treatment PFS/OS
Human ≥ 65 years [19] Myc, BCL2, BCL6 [20] R-CHOP [17] > 8 years [19]
Dog 7 years [12] Myc, BCL2 [21] COP/CHOP 0.7 years
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for about 10 min. Blood was collected at indicated time-
points and serum was frozen for further analysis.
Peptides
Lyophilized dTERT peptides were purchased from JPT 
Peptide Technologies GmbH (Berlin, Germany) and 
resuspended in dimethyl sulfoxide (DMSO) at 40 mg/ml. 
Pools of 15 amino acid peptides overlapping by 11 resi-
dues were assembled as described previously [36]. Four 
pools of 70 peptides (A, B, C and D) were formed for the 
whole length of TERT protein. The final concentration of 
each peptide in the pools was 0.57 mg/ml.
ELISA assay
Antibodies against TERT were measured by ELISA. 96 
well plates were coated with peptide pools diluted at 
1  μg/ml at overnight at 4  °C in coating buffer (carbon-
ate buffer 50  mM pH 9.6). After washing with PBS and 
blocking with 5%BSA PBS-Tween 0.05%, sera from 
DNA–EGT immunized animals were incubated O/N 
at 4  °C at different dilution and revealed by a second-
ary antibody, AP-conjugated goat anti-dog IgG (SIGMA 
A0793, whole molecule) at 1:2000 in 1%BSA PBS-Tween 
0.05% and incubated for 30′ at RT. Plates were read on an 
ELISA reader at  OD405–620. Optical density values were 
plotted.
Statistical analysis
Student’s t-test was performed where indicated. Log-rank 
test was used to evaluate the difference between overall 
survival (OS) between groups.
Results
Study design and Patients
A total of 17, stage III–V dogs were enrolled in this 
trial (Table  2). Dogs were assigned to the treatment 
with Tel-eVax based on owner’s consent. The group 
included 12% intact males, 47% neutered males, 
and 41% neutered females. Breeds included Golden 
Retriever (4), Giant Schnauzer (1), German Shepherd 
(2), Terrier Mix (1), Bassett Hound (1), English Bull-
dog (1), Springer Spaniel (1), Labradoodle (1), Pomera-
nian (1), Shih-tzu (1), Havanese (1) and mixed-breed 
dogs (2). The median age was 84 (range 39–158) 
months. The median weight was 36 (range 5.9–45.0) 
kilograms. All subjects were affected by DLBCL. The 
lymph node involvement was generalized with differ-
ent prevalent locations. Selected animals did not show 
any additional significant disease. Only patient #6902 
developed an Hemangiosarcoma (HSA) 9 months after 
BLBCL diagnosis. All the dogs included in the study 
received a l-CHOP 27-weeks protocol. Patients coded 
3732, 1301, 5767 and 6902 received additional chemo-
therapy. Vaccine began at week 4 at the same date of 
Doxorubicin administration when most dogs (> 50%) 
Table 2 Demographics
MN male neutered, FS female spayed, M male, HSA hemangiosarcoma, BLSA B cell lymphosarcoma, MOPP (M)ustargen (O)ncovin + (P)rocarbazine + (P)rednisone
ID Breed Weight (kg) Gender Age (m) Tumor type Previous treatment Number 
of boosters
3732 G. Schnauzer 40.7 MN 84 DLBCL l-CHOP, bendamustine, epirubicin None
1301 GR 37.5 FS 84 DLBCL l-CHOP, mito/actinomycin, MOPP None
4603 GR 37 M 93 DLBCL l-CHOP 5
5767 GSD 44.4 M 60 DLBCL l-CHOP, MOPP, GS-9219 None
5971 Mix K9 37 MN 141 DLBCL l-CHOP None
6042 Terrier Mix 33.2 MN 45 DLBCL CHOP-MA None
6355 GR 36.7 MN 132 DLBCL l-CHOP None
6377 Bassett 22.6 FS 108 DLBCL l-CHOP None
6902 GSD 40 MN 75 DLBCL, HSA l-CHOP, leukeran None
7402 Mix K9 26.7 FS 132 DLBCL l-CHOP 4
7795 Springer Spaniel 16.3 MN 158 DLBCL l-CHOP None
138 Golden Ret 45.1 FS 52 DLBCL l-CHOP None
387 Labradoodle 34.7 MN 63 DLBCL l-CHOP 3
457 Pomeranian 5.9 FS 49 Stage V BLSA 
(bone marrow)
l-CHOP None
477 Shihtzu 6.5 MN 72 DLBCL l-CHOP None
492 Havanese 22.9 FS 87 DLBCL CHOP 2
1108 GR 38.6 FS 39 DLBCL l-CHOP None
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achieved complete remission. Tel-eVax vaccination 
regimen is shown in Fig. 1a and consisted of two injec-
tions of Ad  (1011 vp) in the biceps femoris at 2 weeks 
interval followed by one or more cycles of three DNA–
EGT (5 mg/injection) every 2 weeks in the tibialis cra-
nialis muscle with a Vet-ePorator™ device (Fig. 1b). An 
8-needle array electrode was utilized in the area fol-
lowing injection with DNA to ensure full coverage by 
the electrical field and appropriate tissue electropora-
tion (Fig. 1c). Most of the dogs received the complete 
treatment consisting of two Ad and 1 DNA–EGT cycle 
(Table  2). The profile of electroporation parameters 
was checked at every DNA administration in real time 
and data were stored into the Vet-ePorator™ archive 
for each single patient.
Tel‑eVax does not show side effects
To assess potential side effects connected with the immu-
notherapy, body weight and temperature were measured 
throughout the entire course of the study. No significant 
changes were noticed during the entire course of the 
study (not shown). To monitor signs of toxicity and/or to 
detect indications of autoimmunity, vaccinated animals 
were constantly monitored for abnormal values in hema-
tological parameters. No significant hematological side 
effects connected with the immunizations were detect-
able in the treated animals.
Tel‑eVax induced Antibody responses
Telomerase reverse transcriptase is a ribonuclear 
protein, however the immunogen was engineered as 
a fusion with Tissue Plasminogen Activator (TPA) 
leader sequence that makes it secreted by muscle cells 
Fig. 1 Vaccination procedure. a Vaccination schedule. Dogs received a l-CHOP 27-weeks protocol and vaccine was administered at week 4, 6 (Ad, 
triangles), 10, 12 and 14 (DNA–EGT, arrows). b Vet-ePorator™ device. Electroporation data are visualized in real time during pulse delivery. c DNA 
injection procedure. Tibialis cranialis muscle is injected with DNA, followed by electrodes insertion and application of electric field
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following DNA–EGT [35]. Therefore, antibodies may 
represent the easier surrogate biomarkers to moni-
tor the immune response in vaccinated dogs. On this 
purpose, we sought to follow antibodies against TERT 
and against the non-self-part of the immunogen, Heat 
labile enterotoxin B (LTB). Since TERT protein is not 
available, we used 4 pools of 15mer peptides overlap-
ping by 11 residues and covering the entire dTERT pro-
tein. Peptides were coated onto ELISA plates (Fig.  2a) 
and dog serum was incubated at different dilution 
to measure antibodies. At day 45 post priming, sera 
from 12 dogs were analyzed by ELISA. We arbitrarily 
assumed as a threshold a signal ∆OD405 > 0.1 compared 
with the DMSO control. As shown in Fig.  2b, most of 
the dogs (8 out of 12) developed a low but detectable 
seroconversion against Pool A, which covers the N-ter-
minal of TERT protein. Poor/no signal was measured 
against Pool B, C, D and LTB. In two dogs (Pt4603 and 
Pt6377) we were able to follow antibody kinetics over 
time (Fig.  2c). These data indicate that dTERT was 
Fig. 2 Antibody detection and kinetics. a representation of the ELISA assay. Peptides are coated on the bottom of plastic wells. Incubation with dog 
sera and detection with a AP-conjugated anti-canine IgG allow signal detection. b Antibody detection in 12 dogs. An arbitrary threshold ∆OD405 
> 0.1 was used to identify responders. c Patient 4603 and patient 6377 antibody kinetics over time
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expressed in  vivo and that antibodies were induced 
upon Tel-eVax™ treatment.
Tel‑eVax prolongs survival of CHOP‑treated canine DLBCL
Tel-eVax/CHOP treated DLBCL dogs have been moni-
tored over time for overall survival (OS). In the moni-
tored period (277  weeks), there have been 94% deaths 
in the group, mostly attributable to DLBCL relapse. The 
95% lower confidence interval for OS of the Tel-eVax/
CHOP group was 452 days, corresponding to 64.5 weeks. 
There was no observable difference in survival both by 
gender and age. The evaluations included all Tel-eVax/
CHOP dogs initiating treatment, irrespective of reason 
for not completing the study. Figure 3 compares the OS 
observed in this study with the Tel-eVax/COP combi-
nation described in Gavazza’s study [34]. Interestingly, 
no significant difference between the two cohorts was 
observed (log-rank test, p = 0.125), confirming the bene-
ficial effect of Tel-eVax™ in addition to chemotherapy for 
DLBCL and increased OS.
Discussion
Lymphoma is the most common hematopoietic tumor in 
dogs. Approximately, 80% are B immunophenotype [36]. 
The standard of care treatment comprises chemotherapy 
with COP or CHOP as the most common protocols and 
often based on user comfort and financial limitations of 
the client. COP chemotherapy regimen can be consid-
ered less effective, as CHOP has shown superior efficacy 
[37]. CHOP consists of a 15–27-week induction protocol 
including an alternating schedule of cyclophosphamide, 
doxorubicin, vincristine and prednisone with or without 
l-asparaginase. Regardless, median survival for canine 
patients is between 275 and 397 days [4–7].
In two previous studies [33, 34], we have shown that 
Tel-eVax is safe, immunogenic and most importantly 
had a significant therapeutic impact on DLBCL dogs 
when combined with COP. dTERT-specific cell mediated 
immune responses were induced in almost all treated 
animals. No adverse effects were observed in any canine 
patient that underwent treatment. In the double arm 
study, the OS time of vaccine/COP treated dogs was sig-
nificantly increased over the COP-only treated cohort 
(> 76.1 vs 29.3  weeks, respectively, p < 0.0001). An open 
question in our previous study was the possibility that 
COP maintenance chemotherapy may act as a immune-
modulator in the vaccination protocol. Some classes of 
chemotherapy drugs may indeed affect antigen cross-
presentation [38], induce a cytokine storm [39], reduce 
the number of regulatory T cells [40, 41], and activate 
homeostatic lymphoid proliferation [42] that could help 
induce the immune response against self-antigens [43]. 
Fig. 3 Kaplan–Meier estimates. Overall Survival in two Lymphoma cohorts treated with Tel-eVax™/Chemotherapy: vaccinated USA (this study) and 
vaccinated Italy [28]. Median survival weeks are shown
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TERT is an interesting and safe immunologic target as it 
is overexpressed mainly by cancer cells. In our experience 
with TERT-immunotherapies we have observed autoim-
munity effects marked by a consistent, although tran-
sient, B-cell depletion after TERT-specific adoptive T cell 
transfer [44] in a rodent model but never with a genetic 
vaccination approach.
In this study, we have combined Tel-eVax with CHOP, 
a dose-intense chemotherapy regimen applied by most 
veterinary oncologists in the United States. The primary 
end point of the study was to assess the efficacy of the 
combination on progression and evolution of canine 
DLBCL overall survival time. No adverse effects were 
observed in any patient, such as significant changes in 
hematological parameters (not shown), or adverse clini-
cal signs, as also not reported by the owners. To further 
follow the immune response in these patients, we have 
tested a novel immunologic assay aiming at detecting 
anti-dTERT antibodies in vaccinated patients’ serum. In 
the absence of the full-length protein, we used pools of 
15mer peptides covering the antigen as a tool to detect 
antibodies. Most of the tested dogs (8 out of 12) mounted 
a low but detectable antibody response (Fig.  2) against 
Pool A, corresponding to the N-terminus of the protein. 
A potential reason may be the presence of B cell epitopes 
present in that pool and exposed on folded protein upon 
secretion. Strikingly, we have not observed antibodies 
against LTB, the non-self-portion of the recombinant 
protein expressed by Tel-eVax. There are two possi-
ble explanations for these findings: (1) TPA-dTERT-
LTB fusion protein is not correctly folded and despite 
its immune-enhancing property, LTB is masked to the 
immune system. This observation is corroborated by the 
low cell mediated immune response against LTB pep-
tides in different TERT fusions in mice [45], dogs [33, 34], 
non-human primates [46] and in a Phase I clinical trial 
in human cancer patients (manuscript in preparation) 
whereas it did not happen with a different fusion part-
ner such as Carcinoembryonic Antigen [47]; (2) since it 
was done with peptides, the assay can only detect linear 
but not conformational epitopes. Therefore, we cannot 
exclude the presence of other antibodies elicited against 
TERT or LTB. The availability of the recombinant pro-
tein or its domains may therefore be instrumental for the 
optimization of the immune assay.
Finally, a significant therapeutic impact on sur-
vival time was observed in the Tel-eVax/CHOP group 
(Fig. 3). The absence of control arm is of course a limi-
tation of our study and therefore we cannot determine 
whether the nature of the combination is synergistic 
and additive. However, we know that the vaccine with-
out chemotherapy does not work [33]. This may be due 
the fact that the immune response takes time to get 
induced and work in a minimal residual disease set-
ting. At any rate, the overall survival of animals was 
452  days, which is far beyond the historical survival 
data reported in literature with CHOP regimens. On 
this basis, a potentiation effect over chemotherapy-only 
seems to be the nature of such combination. Moreo-
ver, since the study was conducted in New York state, 
we have compared our survival data with current data 
relative to Northern United States for DLBCL. An indi-
rect comparison between the 17 patients treated in 
this study with the dog cohort of lymphoma patients 
described in Wilson-Robles et  al. (452 and 244  days, 
respectively) suggest a ~ 2-fold OS increase, in line 
with our previous findings. In addition, no statistical 
difference (p = 0.125) was observed between Tel-eVax/
CHOP and Tel-eVax/COP data generated in our pre-
vious two studies, thus confirming the efficacy of Tel-
eVax in DLBCL. Of note, the minimal effective dose of 
Tel-eVax in dogs has not been yet identified: we used 
 1011 vp Ad or 5 mg DNA plasmid/administration in our 
three studies but we cannot exclude similar antitumor 
effects with lower, saturating doses.
Recently, a conditionally licensed treatment for 
canine lymphoma, Rabacfosadine, has shown substan-
tial single-agent activity in dogs with lymphoma [48]. 
Rabacfosadine treatment resulted in overall response 
rate 84% (68% Complete response, CR; 16% partial 
response, PR with an overall median progression‐free 
interval (PFI) of 194  days (216 for CR and 63 for PR). 
Combining and/or comparing Tel-eVax with rabacfosa-
dine in a future clinical trial would be of great interest. 
More importantly, Tel-eVax concept (Ad + DNA-EP 
targeting hTERT) can be applied to human patients. 
Multiple mechanisms have in fact been shown to 
increase Telomerase activity in hematological malig-
nancies (e.g. epigenetic modulation, amplification of 
the hTERT gene), thus suggesting that TERT may rep-
resent an optimal target for human DLBCL [25].
Conclusions
In summary, our study shows that Tel-eVax is safe and 
has a significant impact on DLBCL canine patients’ sur-
vival when combined with CHOP chemotherapy. Our 
data further supports the clinical use of Tel-eVax in mul-
ticentric DLBCL with application towards conditional 
licensure and warrants the evaluation of this treatment in 
other canine tumor types. Of note, given the increasing 
importance of the dog as translational model for human 
diseases, our data are promising for the evaluation of 
hTERT-targeting immunotherapy for human hematologi-
cal malignancies.
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